|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 21 June 2021, 11:36. The announcement is not marked as price sensitive, and is 16 page(s) in length and 847.66kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.620% short sold according to ASIC data. It was ranked the 241st most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Investor Presentation | 21 June 2021, 11:36 |
| Invex Receives Written Response from FDA on Type C Meeting | 15 June 2021, 8:31 |
| Formulation and Manufacturing Update | 7 May 2021, 8:41 |
| Invex Granted Type C Meeting with FDA | 22 April 2021, 9:29 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 